HINT3 suppresses AKT/mTOR signaling pathway activity during breast cancer tumorigenesis through PTEN transcriptional activation

Li,Jinping; Liu,Yaobang; Lian,Bing; Li,Hong; Chai,Dahai; Gao,Yali; Wang,Yanbai

doi:10.3892/ijmm.2023.5257

HINT3 suppresses AKT/mTOR signaling pathway activity during breast cancer tumorigenesis through PTEN transcriptional activation

Authors:
- Jinping Li
- Yaobang Liu
- Bing Lian
- Hong Li
- Dahai Chai
- Yali Gao
- Yanbai Wang
View Affiliations

Affiliations: Department of Surgical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China
Published online on: May 17, 2023 https://doi.org/10.3892/ijmm.2023.5257
Article Number: 54

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histidine triad nucleotide‑binding protein (HINT) belongs to the histidine triad protein family. Recent studies have demonstrated that HINT1 and HINT2 both play a pivotal role in cancer growth. However, the functions of HINT3 in various types of cancer, including breast cancer (BRCA), have not yet been fully elucidated. In the present study, the role of HINT3 in BRCA was investigated. Based on The Cancer Genome Atlas and reverse transcription‑quantitative PCR analyses, HINT3 was found to be decreased in BRCA tissues. In vitro, HINT3 knockdown promoted the proliferation and colony formation of, and 5‑ethynyl‑2'‑deoxyuridine incorporation in MCF‑7 and MDA‑MB‑231 BRCA cells. By contrast, HINT3 overexpression suppressed DNA synthesis and the proliferation of both cell lines. Apoptosis was also found to be modulated by HINT3. In vivo, HINT3 ectopic expression attenuated the tumorigenesis of MDA‑MB‑231 and MCF‑7 cells in a mouse tumor xenograft model. Furthermore, HINT3 silencing or overexpression also enhanced or inhibited, respectively, the migratory capacity of the MCF‑7 and MDA‑MB‑231 cells. Finally, HINT3 upregulated phosphatase and tensin homolog (PTEN) at the transcriptional level, which resulted in the inactivation of AKT/mammalian target of rapamycin (mTOR) signaling both in vitro and in vivo. Taken together, the present study demonstrates that HINT3 inhibits the activation of the PTEN/AKT/mTOR signaling pathway, and suppresses the proliferation, growth, migration and tumor development of MCF‑7 and MDA‑MB‑231 BRCA cells.

View Figures

View References

1	Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F: Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Waks AG and Winer EP: Breast cancer treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
4	Brenner C: Hint, Fhit, and GalT: Function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry. 41:9003–9014. 2002. View Article : Google Scholar : PubMed/NCBI
5	Su T, Suzui M, Wang L, Lin CS, Xing WQ and Weinstein IB: Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc Natl Acad Sci USA. 100:7824–7829. 2003. View Article : Google Scholar : PubMed/NCBI
6	Li H, Zhang Y, Su T, Santella RM and Weinstein IB: Hint1 is a haplo-insufficient tumor suppressor in mice. Oncogene. 25:713–721. 2006. View Article : Google Scholar : PubMed/NCBI
7	Huang H, Wei X, Su X, Qiao F, Xu Z, Gu D, Fan H and Chen J: Clinical significance of expression of Hint1 and potential epigenetic mechanism in gastric cancer. Int J Oncol. 38:1557–1564. 2011.PubMed/NCBI
8	Zhang YJ, Li H, Wu HC, Shen J, Wang L, Yu MW, Lee PH, Bernard Weinstein I and Santella RM: Silencing of Hint1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma. Cancer Lett. 275:277–284. 2009. View Article : Google Scholar : PubMed/NCBI
9	Li W, Cai S, Wang L, Yang C, Zhou B and Wang H: HINT2 downregulation promotes colorectal carcinoma migration and metastasis. Oncotarget. 8:13521–13531. 2017. View Article : Google Scholar : PubMed/NCBI
10	Zhou DK, Qian XH, Cheng J, Chen LH and Wang WL: Clinical significance of down-regulated HINT2 in hepatocellular carcinoma. Medicine (Baltimore). 98:e178152019. View Article : Google Scholar : PubMed/NCBI
11	Martin J, Magnino F, Schmidt K, Piguet AC, Lee JS, Semela D, St-Pierre MV, Ziemiecki A, Cassio D, Brenner C, et al: Hint2, a mitochondrial apoptotic sensitizer down-regulated in hepatocellular carcinoma. Gastroenterology. 130:2179–2188. 2006. View Article : Google Scholar : PubMed/NCBI
12	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Du L, Li X, Zhen L, Chen W, Mu L, Zhang Y and Song A: Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Mol Med Rep. 17:7163–7169. 2018.PubMed/NCBI
15	Li F, Shi Y, Yang X, Luo Z, Zhang G, Yu K, Li F, Chen L, Zhao Y, Xie Y, et al: Anhydroicaritin inhibits EMT in breast cancer by enhancing GPX1 expression: A research based on sequencing technologies and bioinformatics analysis. Front Cell Dev Biol. 9:7644812022. View Article : Google Scholar : PubMed/NCBI
16	Wang Y, Wu N, Zhang J, Wang H and Men X: MiR-153-5p enhances the sensitivity of triple-negative breast cancer cells to paclitaxel by inducing G2M phase arrest. Onco Targets Ther. 13:4089–4097. 2020. View Article : Google Scholar : PubMed/NCBI
17	Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O and Bargonetti J: Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Res. 21:52019. View Article : Google Scholar : PubMed/NCBI
18	Bachmeier B, Fichtner I, Killian PH, Kronski E, Pfeffer U and Efferth T: Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. PLoS One. 6:e205502011. View Article : Google Scholar : PubMed/NCBI
19	Salic A and Mitchison TJ: A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA. 105:2415–2420. 2008. View Article : Google Scholar : PubMed/NCBI
20	Chou TF, Cheng J, Tikh IB and Wagner CR: Evidence that human histidine triad nucleotide binding protein 3 (Hint3) is a distinct branch of the histidine triad (HIT) superfamily. J Mol Biol. 373:978–989. 2007. View Article : Google Scholar : PubMed/NCBI
21	Huen MSY, Sy SMH and Chen J: BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol. 11:138–148. 2010. View Article : Google Scholar : PubMed/NCBI
22	Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, et al: Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 317:2402–2416. 2017. View Article : Google Scholar : PubMed/NCBI
23	Balmaña J, Diez O, Rubio IT and Cardoso F; ESMO Guidelines Working Group, : BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol. 22 (Suppl 6):vi31–vi34. 2011. View Article : Google Scholar : PubMed/NCBI
24	Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F and Senkus E; ESMO Guidelines Committee, : Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 27 (Suppl 5):v103–v110. 2016. View Article : Google Scholar : PubMed/NCBI
25	Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, et al: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 534:47–54. 2016. View Article : Google Scholar : PubMed/NCBI
26	Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, et al: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 379:753–763. 2018. View Article : Google Scholar : PubMed/NCBI
27	Ozga M: HINT1-a novel tumor suppressor protein of the HIT superfamily. Postepy Biochem. 56:55–60. 2010.(In Polish). PubMed/NCBI
28	Martin J, St-Pierre MV and Dufour JF: Hit proteins, mitochondria and cancer. Biochim Biophys Acta. 1807:626–632. 2011. View Article : Google Scholar : PubMed/NCBI
29	Worby CA and Dixon JE: Pten. Annu Rev Biochem. 83:641–669. 2014. View Article : Google Scholar : PubMed/NCBI
30	Manning BD and Cantley LC: AKT/PKB signaling: Navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
31	Fan H, Wu Y, Yu S, Li X, Wang A, Wang S, Chen W and Lu Y: Critical role of mTOR in regulating aerobic glycolysis in carcinogenesis (review). Int J Oncol. 58:9–19. 2021. View Article : Google Scholar : PubMed/NCBI
32	Wang J, Liang D, Zhang XP, He CF, Cao L, Zhang SQ, Xiao X, Li SJ and Cao YX: Novel PI3K/Akt/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy. Int J Oncol. 58:70–82. 2021. View Article : Google Scholar : PubMed/NCBI
33	Costa C, Wang Y, Ly A, Hosono Y, Murchie E, Walmsley CS, Huynh T, Healy C, Peterson R, Yanase S, et al: PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer. Cancer Discov. 10:72–85. 2020. View Article : Google Scholar : PubMed/NCBI
34	Pandolfi PP: Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med. 351:2337–2338. 2004. View Article : Google Scholar : PubMed/NCBI
35	Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1943–1947. 1997. View Article : Google Scholar : PubMed/NCBI
36	Donia M, McCubrey JA, Bendtzen K and Nicoletti F: Potential use of rapamycin in HIV infection. Br J Clin Pharmacol. 70:784–793. 2010. View Article : Google Scholar : PubMed/NCBI
37	Basile MS, Cavalli E, McCubrey J, Hernández-Bello J, Muñoz-Valle JF, Fagone P and Nicoletti F: The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. Drug Discov Today. 27:848–856. 2022. View Article : Google Scholar : PubMed/NCBI
38	Mammana S, Bramanti P, Mazzon E, Cavalli E, Basile MS, Fagone P, Petralia MC, McCubrey JA, Nicoletti F and Mangano K: Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. Oncotarget. 9:8263–8277. 2018. View Article : Google Scholar : PubMed/NCBI
39	Ji L, Xie W and Zhang Z: Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Semin Arthritis Rheum. 50:1073–1080. 2020. View Article : Google Scholar : PubMed/NCBI